4.8 Article

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

期刊

CANCER CELL
卷 39, 期 4, 页码 494-+

出版社

CELL PRESS
DOI: 10.1016/j.ccell.2021.01.003

关键词

-

资金

  1. NCI [CA166974-01A1]
  2. New York State Empire Investment Program
  3. Stony Brook Renaissance School of Medicine
  4. Stony Brook Cancer Center
  5. TRO Carol M. Baldwin Award
  6. Stony Brook Cancer Center Bahl IDEA Award
  7. Lynn November Pilot Funds for Therapeutic Development in Aggressive Breast Cancer from the Stony Brook Cancer Center

向作者/读者索取更多资源

Mtp53 suppresses innate immune response by interfering with cytoplasmic DNA sensing mechanism, leading to altered cytokine production and immune evasion. Restoring TBK1 signaling bypasses mtp53 and restores immune cell function, potentially eliminating mtp53 tumors.
Mutant p53 (mtp53) proteins can exert cancer-promoting gain-of-function activities. We report a mechanism by which mtp53 suppresses both cell-autonomous and non-cell-autonomous signaling to promote cancer cell survival and evasion of tumor immune surveillance. Mtp53 interferes with the function of the cytoplasmic DNA sensing machinery, cGAS-STING-TBK1-IRF3, that activates the innate immune response. Mtp53, but not wild-type p53, binds to TANK-binding protein kinase 1 (TBK1) and prevents the formation of a trimeric complex between TBK1, STING, and IRF3, which is required for activation, nuclear translocation, and transcriptional activity of IRF3. Inactivation of innate immune signaling by mtp53 alters cytokine production, resulting in immune evasion. Restoring TBK1 signaling is sufficient to bypass mtp53 and lead to restored immune cell function and cancer cell eradication. This work is of translational interest because therapeutic approaches that restore TBK1 function could potentially reactivate immune surveillance and eliminate mtp53 tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据